{
    "clinical_study": {
        "@rank": "100765", 
        "acronym": "ICARuS", 
        "arm_group": [
            {
                "arm_group_label": "Appendiceal, no chemotherapy within 6 months prior to surgery", 
                "arm_group_type": "Experimental", 
                "description": "First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the Colorectal Disease Management Team.\nExposure to chemotherapy in the prior 6 months vs. no such exposure\nAppendix vs. Colon or Rectum Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
            }, 
            {
                "arm_group_label": "Appendiceal, chemotherapy within 6 months prior to surgery", 
                "arm_group_type": "Experimental", 
                "description": "First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the Colorectal Disease Management Team.\nExposure to chemotherapy in the prior 6 months vs. no such exposure\nAppendix vs. Colon or Rectum \u2022 Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
            }, 
            {
                "arm_group_label": "Colorectal, no chemotherapy within 6 months prior to surgery", 
                "arm_group_type": "Experimental", 
                "description": "First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the Colorectal Disease Management Team.\nExposure to chemotherapy in the prior 6 months vs. no such exposure\nAppendix vs. Colon or Rectum \u2022 Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
            }, 
            {
                "arm_group_label": "Colorectal, chemotherapy within 6 months prior to surgery", 
                "arm_group_type": "Experimental", 
                "description": "First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the Colorectal Disease Management Team.\nExposure to chemotherapy in the prior 6 months vs. no such exposure\nAppendix vs. Colon or Rectum \u2022 Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
            }
        ], 
        "brief_summary": {
            "textblock": "This is the first randomized trial comparing Early post-operative intraperitoneal\n      chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal\n      and colorectal cancer. The purpose of this study is to find out what effects, good and/or\n      bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal,\n      rectal or colon cancer."
        }, 
        "brief_title": "ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Appendix Cancer", 
            "Colorectal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Appendiceal Neoplasms", 
                "Colorectal Neoplasms", 
                "Fever", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient's age 18 years or older, both genders.\n\n          -  Clinical diagnosis of appendiceal or colorectal neoplasm with peritoneal mucinosis or\n             metastasis.\n\n          -  Patient must be planning to undergo complete cytoreduction of all peritoneal disease.\n\n          -  ECOG performance status \u2264 1.\n\n          -  Hematology: ANC \u2265 1,500/ \u03bcL; Platelets > 100,000/ \u03bcL.\n\n          -  Adequate Renal function Creatinine <1.5 x the upper limit of normal (ULN) or\n             calculated creatinine clearance of \u2265 50ml/min.\n\n          -  Adequate Hepatic function: Bilirubin less than 1.5mg/dL; (except in patients with\n             Gilbert's Syndrome, who must have a total bilirubin less than 3.0mg/dL).\n\n          -  Women with childbearing potential who are negative for pregnancy test (urine or\n             blood) and who agree to use effective contraceptive method. Reliable contraception\n             should be used from trial screening and must be continued throughout the study. A\n             woman of childbearing potential is defined as one who is biologically capable of\n             becoming pregnant.\n\n          -  A man participating in this study must agree to utilize reliable barrier form of\n             contraception for the duration of the study.\n\n          -  Signed and dated written informed consent to participate in this clinical trial must\n             be obtained prior to any study procedure.\n\n          -  Subjects with a history of endometrial cancer are eligible only if they presented\n             with a stage lower than 1A and if the histology was a subtype other than poorly\n             differentiated.\n\n        Exclusion Criteria:\n\n          -  Subjects who have previously undergone complete cytoreduction and/or intraperitoneal\n             chemotherapy.\n\n          -  Subjects with classical carcinoid\n\n          -  Tumors of low malignant potential\n\n          -  Subjects who have received prior radiation to any portion of the abdominal cavity or\n             pelvis are excluded.\n\n        Other prior malignancies, except for cured non-melanoma skin cancer, or curatively treated\n        in situ carcinoma of the cervix, or adequately treated malignancies for which there has\n        been no evidence of activity for more than 3 years.\n\n          -  Presence of clinically apparent or suspected metastasis to sites other than lymph\n             nodes or peritoneal surfaces.\n\n          -  Women who are pregnant or lactating.\n\n          -  Subjects with a condition which may interfere with the subjects' ability to\n             understand the requirements of the study.\n\n          -  Known HIV, Hepatitis B or Hepatitis C positive.\n\n          -  Active coronary artery disease (defined as unstable angina or a positive cardiac\n             stress test).\n\n          -  Subjects with a history of coronary artery disease may be included if they have had a\n             normal stress test within 30 days of enrollment.\n\n        Uncontrolled hypertension defined as >140/90 and not cleared for surgery at the time of\n        consent.\n\n          -  New York Heart Association (NYHA) Class II or higher Congestive heart failure.\n\n          -  Restrictive or obstructive pulmonary disease that would limit study compliance or\n             place the patient at unacceptable risk for participation in the study.\n\n          -  History of cerebrovascular disease. that would limit study compliance or place the\n             patient at unacceptable risk for participation in the study.\n\n        Subjects with other concurrent severe medical problems unrelated to the malignancy that\n        would significantly limit full compliance with the study, or places them at an\n        unacceptable risk for participation in the study.\n\n          -  Patients with known floxuridine, leucovorin ,or mitomycin allergy.\n\n          -  Evidence of extensive intraperitoneal adhesions at the time of surgery which\n             prohibits intraperitoneal therapy, as determined by the operating surgeon.\n\n          -  Any condition that would preclude the ability to deliver appropriate IP therapy.\n\n          -  Life expectancy < 12 weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01815359", 
            "org_study_id": "12-289"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Appendiceal, no chemotherapy within 6 months prior to surgery", 
                    "Appendiceal, chemotherapy within 6 months prior to surgery", 
                    "Colorectal, no chemotherapy within 6 months prior to surgery", 
                    "Colorectal, chemotherapy within 6 months prior to surgery"
                ], 
                "description": "Optimal Surgical Debulking", 
                "intervention_name": "Cytoreductive Surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Appendiceal, no chemotherapy within 6 months prior to surgery", 
                    "Appendiceal, chemotherapy within 6 months prior to surgery", 
                    "Colorectal, no chemotherapy within 6 months prior to surgery", 
                    "Colorectal, chemotherapy within 6 months prior to surgery"
                ], 
                "intervention_name": "HIPEC with Mitomycin-C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Appendiceal, no chemotherapy within 6 months prior to surgery", 
                    "Appendiceal, chemotherapy within 6 months prior to surgery", 
                    "Colorectal, no chemotherapy within 6 months prior to surgery", 
                    "Colorectal, chemotherapy within 6 months prior to surgery"
                ], 
                "intervention_name": "EPIC with FUDR and Leucovorin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mitomycins", 
                "Mitomycin", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ICARuS", 
            "Intraperitoneal Chemotherapy", 
            "hyperthermic intraperitoneal chemotherapy", 
            "Optimal Surgical Debulking", 
            "Leucovorin", 
            "Floxuridine (FUDR)", 
            "Mitomycin", 
            "12-289"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Garrett Nash, MD, MPH", 
                "phone": "646-888-3086"
            }, 
            "contact_backup": {
                "last_name": "Andrea Cercek, MD", 
                "phone": "646-888-4189"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }, 
            "investigator": {
                "last_name": "Garrett Nash, MD, MPH", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Single-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis", 
        "overall_contact": {
            "last_name": "Garrett Nash, MD, MPH", 
            "phone": "646-888-3086"
        }, 
        "overall_contact_backup": {
            "last_name": "Andrea Cercek, MD", 
            "phone": "646-888-4189"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Garrett Nash, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Documentation of tumor recurrence will be made based on surveillance CT scans at time points as determined by attending radiologist, with clinical correlation from the treating physician.", 
            "measure": "disease-free survival", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01815359"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "We will evaluate toxicity up to 60 days postoperatively for any surgical Grade 3-5 complications or chemotherapy related Grade 4 or 5 toxicities. Surgical morbidity will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0", 
                "measure": "surgical toxicity grade 3 to 5", 
                "safety_issue": "Yes", 
                "time_frame": "up to 60 days"
            }, 
            {
                "description": "We will evaluate toxicity up to 60 days postoperatively for any surgical Grade 3-5 toxicity or chemotherapy related Grade 4 or 5 toxicities.", 
                "measure": "chemotherapy toxicity grade 4 or 5", 
                "safety_issue": "Yes", 
                "time_frame": "up to 60 days"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}